



## Comparison of Effectiveness and Safety for the Apixaban and Low-Molecular-Weight Heparin in Prevention of Deep Vein Thrombosis after Hip Replacement

Lin WANG \*, Jia-bin XIE, & Qiu-wei LI

Department of Orthopaedics, The Yijishan Hospital of Wannan Medical College,  
Western Zheshan Road 2, Wuhu 241002, Anhui, People's Republic of China

**SUMMARY.** The aim was to analyze the efficacy and safety of apixaban versus low-molecular-weight heparin (LMWH) for the prevention of deep venous thrombosis after the hip arthroplasty. Fifty patients with primary unilateral hip arthroplasty in The Yijishan Hospital of Wannan medical College between January 2020 and December 2020 were selected, which were randomly divided into apixaban group and low-molecular-weight heparin group. They were given drugs at 6 h after replacement, the patients in the apixaban group were given apixaban 5 mg/day with the course of 5 weeks; the another were given low-molecular-weight heparin 4 100 U/d with the course of 2 weeks. There were no significant differences between two groups ( $p > 0.05$ ). The results indicate that full course of apixaban has clear effect and reliable security in the prevention of deep venous thrombosis after hip arthroplasty.

**RESUMEN.** El objetivo fue analizar la eficacia y seguridad del apixaban frente a la heparina de bajo peso molecular (HBPM) para la prevención de la trombosis venosa profunda tras la artroplastia de cadera. Se seleccionaron 50 pacientes con artroplastia unilateral de cadera primaria en el Hospital Yijishan de Wannan Medical College entre enero de 2020 y diciembre de 2020, que se dividieron aleatoriamente en grupo de apixaban y grupo de heparina de bajo peso molecular. Se les administró fármacos a las 6 h del recambio, los pacientes del grupo apixaban recibieron 5 mg/día de apixaban en el transcurso de 5 semanas; a los demás se les administró heparina de bajo peso molecular 4100 U/día en el transcurso de 2 semanas. No hubo diferencias significativas entre los dos grupos ( $p > 0.05$ ). Los resultados indican que el ciclo completo de apixaban tiene un efecto claro y una seguridad confiable en la prevención de la trombosis venosa profunda después de la artroplastia de cadera.

**KEY WORDS:** apixaban, deep venousthrombosis (DVT), low-molecular-weight heparin (LMWH).

\* Author to whom correspondence should be addressed. *E-mail:* 53113653@qq.com